Overview

* RAPT Q2 net loss narrows to $17.6 mln from $27.7 mln last year

* Research and development expenses drop; General and administrative expenses rise

Result Drivers

* R&D EXPENSES - Decreased to $12.3 mln on reduced spending on zelnecirnon and tivumecirnon, offset by increased costs for RPT904 and early-stage programs

* G&A EXPENSES - Increased to $7.2 mln primarily due to higher consulting and facilities costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$17.64

Income mln

Q2 Basic -$0.65

EPS

Q2 $19.54

Operatin mln

g

Expenses

Q2 -$19.54

Operatin mln

g Income

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)